These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23931337)

  • 1. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
    Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
    Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal use of bisphosphonates in patients with multiple myeloma.
    Terpos E; Roodman GD; Dimopoulos MA
    Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
    Miwa A
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients.
    Zhang X; Chang C; Zhao Y; Wu L; Zhang Z; Li X
    Hematology; 2012 Sep; 17(5):255-60. PubMed ID: 22971530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
    Ural AU; Avcu F
    Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
    Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
    Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of bone lesions in multiple myeloma].
    Hata H; Mitsuya H
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
    Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D
    Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924
    [No Abstract]   [Full Text] [Related]  

  • 11. Atraumatic bone pain in multiple myeloma secondary to bisphosphonate-related bone injury.
    Williams R; Wolger L; Alajangi R
    Br J Haematol; 2021 Jan; 192(2):229. PubMed ID: 33094837
    [No Abstract]   [Full Text] [Related]  

  • 12. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers of bone turnover in diagnosis of myeloma bone disease.
    Dizdar O; Barista I; Kalyoncu U; Karadag O; Hascelik G; Cila A; Pinar A; Celik I; Kars A; Tekuzman G
    Am J Hematol; 2007 Mar; 82(3):185-91. PubMed ID: 17022050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.
    Zaidi M; Epstein S; Friend K
    Ann N Y Acad Sci; 2006 Apr; 1068():560-3. PubMed ID: 16831952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
    Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bisphosphonates in multiple myeloma.
    Levy J; Roodman GD
    Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma.
    Kuliszkiewicz-Janus M; Małecki R; Zółtaszek A; Zastawny M
    Leuk Lymphoma; 2005 Dec; 46(12):1749-53. PubMed ID: 16263577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.